Celgene Corp. suffered a setback to its ambitions in B-cell lymphomas with the announcement that the Phase III ORIGIN trial of Revlimid in treatment-naïve, elderly chronic lymphocytic leukemia patients must stop due to a higher death rate in the lenalidomide arm.
Celgene announced July 18 that FDA had placed the ORIGIN study in first-line treatment of elderly CLL patients on hold...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?